Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
; : 286-290, 2011.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-45123
Responsible library:
WPRO
ABSTRACT
Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of administering erlotinib as a second EGFR TKI after resistance of gefitinib as the first TKI has been well known. However, good response to gefitinib after an initial response to erlotinib has been rare. We report that a 45-year-old woman (never smoked), with lung adenocarcinoma and EGFR mutation, showed an initial response to erlotinib, and then responded to gefitinib again.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Quinazolines
/
Protein-Tyrosine Kinases
/
Adenocarcinoma
/
ErbB Receptors
/
Erlotinib Hydrochloride
/
Lung
/
Lung Neoplasms
Limits:
Female
/
Humans
Language:
Korean
Journal:
Tuberculosis and Respiratory Diseases
Year:
2011
Document type:
Article